Miranda Hooker

Miranda Hooker is a partner in the Complex Litigation & Dispute Resolution group at Goodwin. She joined the firm in 2023. Miranda represents clients in government investigations, including those involving health care fraud and abuse matters. Leveraging her background as a former federal healthcare fraud prosecutor, she helps pharmaceutical, medical device and health care companies navigate federal criminal, civil and state attorney general investigations and enforcement actions. Having tried and defended significant cases in matters involving the False Claims Act, Anti-Kickback Statute, Controlled Substances Act, HIPAA, and Stark Law, Miranda also brings her prosecutorial background to bear in conducting internal investigations for corporate clients in the health care and financial services industries, among others. In addition, Miranda serves as outside compliance counsel for pharmaceutical and medical device manufacturers, diagnostic laboratories, healthcare providers, and pharmacies.

Miranda is a skilled trial attorney with deep experience defending companies and individuals in criminal and civil government investigations and enforcement actions brought by the Department of Justice, Securities and Exchange Commission, State Attorney Generals, and other regulatory agencies.  Representative examples of Miranda’s experience include: 

• Represented numerous international pharmaceutical and medical device companies in federal criminal health care fraud investigations*
• Represented dozens of pharmaceutical and medical device company executives and employees in criminal health care fraud investigations*
• Represented medical device executive in criminal off-label promotion case that resulted in dismissal of the indictment by the United States*
• Represented online, retail, and long-term care pharmacies in criminal and civil investigations into violations of the Controlled Substances Act and False Claims Act
• Represented corporate general counsel in federal criminal environmental crime cases that resulted in dismissal of the indictment by the United States*
• Represented parent in “Varsity Blues” college admissions case*
• Represented skilled nursing and long term care facilities in federal criminal and civil healthcare fraud investigations*
• Conducted numerous internal and SEC investigations, including for Boards of Directors and Special Committees, into matters involving embezzlement, revenue recognition, stock option compensation, health care fraud, and alleged violations of the Foreign Corrupt Practices Act*
• Represented defense and government contractors in False Claims Act litigation*
• Defended companies against allegations of breach of fiduciary duty claims arising out of mergers and acquisitions and public offerings*
• Conducted internal investigation for diagnostic laboratory into allegations of improper sales practices and violations of the Anti-Kickback Statute and HIPAA*
• Advised companies on compliance policies and matters relating to payments to health care providers*
• Advised companies on health care regulatory issues relating to mergers and acquisitions*
• Represented an international adoption agency in matters relating to allegations of consumer and other fraud*

*Denotes experience prior to joining Goodwin.

Before joining the firm, Miranda served as an Assistant U.S. Attorney in the Health Care Fraud Unit of the U.S. Attorney’s Office for the District of Massachusetts, where she was responsible for investigating and prosecuting Medicare and Medicaid fraud; violations of FDA laws and regulations, including allegations of off-label marketing and violations of the Anti-Kickback Statute; and drug diversion by hospitals, physicians, and other health care providers. Miranda also worked in the Narcotics and Money Laundering Unit and with the Civil Rights Enforcement Team.

Before joining the U.S. Attorney’s Office, Miranda served as counsel at a global law firm in Boston, where she worked on a number of high-profile government enforcement matters and conducted internal investigations into allegations of health care fraud, securities fraud, accounting fraud, and environmental crimes. Miranda also worked as a Special Assistant District Attorney for the Middlesex County District Attorney’s Office where she prosecuted felony cases and conducted several jury trials and evidentiary hearings. 

Miranda is a frequent speaker on health care fraud enforcement and corporate compliance practices.

• LMG Life Sciences Americas Awards 2024 – Government Investigations Attorney of the Year
• Boston Magazine, Top Lawyers List, Criminal Defense White Collar, 2021-22
• Chambers USA: Litigation: White-Collar Crime & Government Investigations, Massachusetts, 2022-2024
• Best Lawyers in America®: Criminal Defense: White-Collar, 2022-2025
• Massachusetts Super Lawyers list, 2019-2022
• Recommended for Corporate Investigations and White-Collar Criminal Defense in The Legal 500 United States, 2024
• Recommended for Healthcare: Service Providers in The Legal 500 United States, 2024

• Co-Author, “A Deep Dive into the Foreign Corrupt Practices Act,” Global Investigations Review’s The Guide to Monitorships – Fourth Edition, May 2024
• Panelist, “The False Claims Act: Enforcement Priorities and the Evolving Landscape of FCA Investigations and Litigation,” Boston Bar Association’s Annual White Collar Conference, May 2, 2024
• Speaker, “Webinar: Rethinking BYOD Policies and Device Management after DOJ Revisions to Corporate Criminal Enforcement Policies,” Troutman Pepper, December 15, 2022
• Speaker, “MAC, OIG, or DOJ? The ABCs of Overpayments and Self-Disclosures,” American Health Law Association’s Fraud and Compliance Forum 2022, September 29, 2022
• Presenter, “Private Equity Investment Risks in Healthcare,” ABA’s 32nd Annual National Institute on Health Care Fraud, June 23, 2022
• Panelist, “Healthcare Fraud Update,” Boston Bar Association’s Annual White Collar Conference on the Health Care Fraud Enforcement, May 5, 2022
• Panelist, “3rd Annual Hot Trends in SEC and DOJ Enforcement and Litigation 2022”, New England Conference, February 1, 2022
• Speaker, “ Everything You Wanted to Know About Federal Investigations but Were Afraid to Ask,” American Health Law Association Annual Meeting 2021, June 30, 2021
• Speaker, “Anti-Kickback Statute Enforcement Year in Review and Outlook for 2021,” Troutman Pepper Webinar, March 25, 2021
• Speaker, “COVID-19: A Year Later. Where Do We Go From Here?,” Troutman Pepper, March 23, 2021
• Co-Author, “Limiting PE Firms’ Exposure to FCA Liability for Alleged Misconduct by Portfolio Companies,” Troutman Pepper, July 19, 2022
• Co-Author, “OIG: Continuing Education Programs Have Independent Value Under AKS,” Troutman Pepper, July 18, 2022
• Co-Author, “The 2021 Anti-Kickback Statute Year in Review and 2022 Outlook: What’s Old Is New,” Pratt’s Government Contracting Law Report, May 2022
• Co-Author, “2022 Updates to the AdvaMed Code: What You Need to Know,” Troutman Pepper, March 23, 2022
• Co-Author, “The Case for Early-Stage Compliance,” ABA/CJS White Collar Crime Committee Newsletter, Winter/Spring 2022
• Co-Author, “The 2021 Anti-Kickback Statute Year in Review and 2022 Outlook: What’s Old Is New,” Troutman Pepper, February 28, 2022
• Co-Author, “DOJ Announces Major Changes to Its Corporate Enforcement Policies,” Troutman Pepper, November 2, 2021
• Co-Author, “The AKS “Means What It Says” — But Some Manufacturers and Patients Are Still Between a Rock and a Hard Place on Copay Assistance,” Troutman Pepper, October 11, 2021
• Co-Author, “Senate Proposal Opens the Door for Increase in State Attorneys General Antitrust Lawsuits,” Troutman Pepper, October 7, 2021
• Co-Author, “The Case for Early-Stage Compliance,” Troutman Pepper, September 1, 2021
• Co-Author, “Revised PhRMA Code Responds to OIG Special Fraud Alert on Speaker Programs,” Troutman Pepper, August 17, 2021
• Co-Author, “Recent Developments in Auditing Could Create Tensions, Leading to More Regulatory Actions,” Troutman Pepper, July 2, 2021
• Podcast, “Healthcare Entrepreneurship Must-Have: Putting Compliance Front and Center,” Integrity Through Compliance Podcast, June 4, 2021
• Co-Author, “DOJ’s Robust 2020 Pandemic Response Signals Increasing Focus on COVID-19-Related Fraud in 2021,” Troutman Pepper, March 10, 2021
• Co-Author, “DC Taxpayers Face More Scrutiny Under New False Claims Act,” Law360, February 18, 2021
• Co-Author, “Anti-Kickback Statute Enforcement Year in Review and Outlook for 2021,” Troutman Pepper, February 1, 2021
• Co-Author, “Amending DC’s False Claims Act: Expansion of the DC AG’s Power Through Removal of the Tax Bar,” Troutman Pepper State Attorneys General Monitor, February 2021
• Co-Author, “Protecting Trade Secrets: Lessons Learned from the Levandowski Case,” Intellectual Property & Technology Law Journal, January 2021
• Co-Author, “Criminal Antitrust Anti-Retaliation Act Signed Into Law,” The American Bar Association, December 2020
• Co-Author, “The Coming Tsunami: Anticipated Regulatory and Enforcement Trends in the Wake of COVID-19 and the Unique Role of State Attorneys General,” Business Law Today, June 10, 2020
• Quoted, “Fraud Is the Killjoy at the Telehealth Party,” Politico, August 7, 2022
• Quoted, “With Cerebral in the Spotlight, DOJ, Regulators to Ramp Up Scrutiny of Telehealth Startups, Former Prosecutor Says,” FIERCE Healthcare, July 5, 2022
• Quoted, “Docs Faked Patient Visits and Orders; Caught in Telehealth Crime,” Medscape Medical News, March 9, 2022
• Quoted, “Telehealth, Electronic Records Draw Anti-Kickback Attention,” Bloomberg Law, February 25, 2021
• Quoted, “What Should a GC Do When the Boss Is Mentally Unfit?,” Law360, September 28, 2020